Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
, 20 (2), 153-61; discussion 162, 166, 169 passim

Targeting the Epidermal Growth Factor Receptor. Trials in Head and Neck and Lung Cancer

Affiliations
  • PMID: 16562649
Review

Targeting the Epidermal Growth Factor Receptor. Trials in Head and Neck and Lung Cancer

Nabil F Saba et al. Oncology (Williston Park).

Abstract

The epidermal growth factor receptor (EGFR) promotes the growth of different cell types and has been implicated in tumorigenesis. The EGFR comprises a family of four structurally similar tyrosine kinases with a complex link to downstream signaling molecules that ultimately regulate key cell processes. Anti-EGFR agents have been developed as promising therapeutic anticancer targets, and some have been recently approved for the treatment of non-small-cell lung cancer and colon cancer. The two anti-EGFR therapies with the greatest clinical application are monoclonal antibodies that block the binding of ligands to EGFR and small-molecule tyrosine kinase inhibitors that inhibit the binding of adenosine triphosphate to the internal tyrosine kinase receptor of EGFR. We attempt to give an overview of the EGFR function and biology, focusing on the most important clinical findings and applications of EGFR inhibitors in lung and head and neck cancer.

Similar articles

See all similar articles

Cited by 7 articles

See all "Cited by" articles

MeSH terms

Feedback